Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeks

ApprovedTerminated

2 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Nov 1, 2008 → Jun 1, 2010

NCT ID

NCT00752622

About Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeks

Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeks is a approved stage product being developed by Merck for Crohn's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00752622. Target conditions include Crohn's Disease.

What happened to similar drugs?

8 of 20 similar drugs in Crohn's Disease were approved

Approved (8) Terminated (3) Active (12)

✅adalimumabAbbVieApproved

✅Infliximab + Prednisolone + AzathioprinePfizerApproved

✅Celebrex + placeboPfizerApproved

✅Cimzia + MesalamineUCBApproved

✅Certolizumab PegolUCBApproved

✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

✅natalizumabBiogenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00752622	Approved	Terminated	Nov 1, 2008	Jun 1, 2010	Crohn's Disease

Competing Products

20 competing products in Crohn's Disease

See all competitors

Product	Company	Stage	Hype Score
CT-P13 + Remicade	Celltrion	Phase 3	40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 1	29
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
CP-461	Astellas Pharma	Phase 2	35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg	Eisai	Phase 1/2	32
E6011 + Placebo	Eisai	Phase 2	35
E6011 + Placebo	Eisai	Phase 1	21
adalimumab + adalimumab + placebo	Eisai	Phase 2/3	38
adalimumab	Eisai	Phase 2/3	38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 3	47
Mirikizumab + Mirikizumab + Tirzepatide + Placebo	Eli Lilly	Phase 3	47
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
Mirikizumab	Eli Lilly	Phase 3	44
Matching Placebo for Upadacitinib + Upadacitinib	AbbVie	Phase 3	40
Adalimumab + Placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo for Upadacitinib	AbbVie	Phase 3	40
Placebo + ABT-494	AbbVie	Phase 2	35
ABT-494	AbbVie	Phase 2	35
Risankizumab + Comparator	AbbVie	Pre-clinical	33